SCHEMBL8043472

SCHEMBL8043472

O=C1CC(O)Oc2ccccc21

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOB P27338 7/20 0.61
ADORA3 P0DMS8 3/20 0.61
AR P10275 3/20 0.61
CYP19A1 P11511 2/20 0.61
KDM4E B2RXH2 1/20 0.61
HSD17B10 Q99714 1/20 0.61
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
MAPT P10636 2/20 0.57
HSD11B1 P28845 1/20 0.57
AKR1C3 P42330 1/20 0.57
CYP3A4 P08684 1/20 0.57
MAPK1 P28482 1/20 0.57
AXL P30530 1/20 0.53
MAOA P21397 2/20 0.45
SIGMAR1 Q99720 1/20 0.44
ABCB1 P08183 1/20 0.44
PSMB5 P28074 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30274254 1.00 MAOB (0.61) MAOBADORA3ARCYP19A1KDM4E
Trifluoroacetic Acid SCHEMBL30260083 0.87 MAOB (0.53) MAOBADORA3ARCYP19A1KDM4E
SCHEMBL8373024 0.78 MAOB (0.62) MAOBADORA3ARCYP19A1KDM4E
SCHEMBL10344116 0.78 MAOB (0.62) MAOBADORA3ARCYP19A1KDM4E
SCHEMBL24969554 0.77 MAOB (0.61) MAOBADORA3ARCYP19A1KDM4E
SCHEMBL15147107 0.77 MAOB (0.61) MAOBADORA3ARCYP19A1KDM4E
SCHEMBL9819236 0.77 MAOB (0.61) MAOBADORA3ARCYP19A1KDM4E
SCHEMBL8185206 0.77 MAOB (0.61) MAOBADORA3ARCYP19A1KDM4E
SCHEMBL69392 0.77 MAOB (0.61) MAOBADORA3ARCYP19A1KDM4E
SCHEMBL27956971 0.77 MAOB (0.61) MAOBADORA3ARCYP19A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6096907-A REDUCING A 7-HYDROXY-4-CHROMANONE OR DERIVATIVE WITH ZINC AND AN ACID BASF AKTIENGESELLSCAHFT (DE) 2000-08-01 US claimed
US-12162863-B2 Modulators of stimulator of interferon genes (STING) Ryvu Therapeutics S.A. (PL) 2024-12-10 US disclosed
CN-115925665-B PDE4 inhibitor and application thereof 中国药科大学 2024-06-25 CN disclosed
CN-115925665-A PDE4 inhibitor and application thereof 中国药科大学 2023-04-07 CN disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 US disclosed
WO-2019238786-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2019-12-19 WO disclosed
US-20150141241-A1 SEPARATING AGENT FOR OPTICAL ISOMER National University Corporation Nagoya University a corporation 2015-05-21 US disclosed
EP-2758366-A1 PROCESS FOR PREPARING CHIRAL QUINONE DSM IP Assets B.V. (NL) 2014-07-30 EP disclosed
WO-2013041676-A1 PROCESS FOR PREPARING CHIRAL QUINONE DSM IP ASSETS B.V. (NL) 2013-03-28 WO disclosed
CN-1116292-C Process for preparing benzodihydropyranol deriv. BASF AG (DE) 2003-07-30 CN disclosed
US-6096907-A REDUCING A 7-HYDROXY-4-CHROMANONE OR DERIVATIVE WITH ZINC AND AN ACID BASF AKTIENGESELLSCAHFT (DE) 2000-08-01 US disclosed
US-6096907-A REDUCING A 7-HYDROXY-4-CHROMANONE OR DERIVATIVE WITH ZINC AND AN ACID BASF AKTIENGESELLSCAHFT (DE) 2000-08-01 US disclosed
CN-1249306-A Process for preparing benzodihydropyranol deriv. BASF AG (DE) 2000-04-05 CN disclosed
JP-2000095776-A PRODUCTION OF CHROMANOL DERIVATIVE BASF AG 2000-04-04 JP disclosed
EP-0989126-A1 Process for the production of chromanol derivatives BASF AKTIENGESELLSCHAFT (DE) 2000-03-29 EP disclosed
US-4968819-A CATALYTIC SELECTIVE ETHERIFICATION ALKALOIDA VEGYESZETI GYAR (HU) 1990-11-06 US disclosed
US-4882353-A ANTICOAGULANTS, VASODILATION, AND BRONCHODILATOR AGENT BAYER AKTIENGESELLSCHAFT (DE) 1989-11-21 US disclosed
US-4866089-A 7-ALKOXY-8-METHOXY-2,2-DIMETHYL-2H-CHROMENES; INSECTICIDES, NEMATOCIDES ALKALOIDA VEGYESZETI GYAR (HU) 1989-09-12 US disclosed
EP-0315009-A2 Chroman derivatives, process for their preparation and their use in medicines BAYER AG (DE) 1989-05-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162863-B2 Modulators of stimulator of interferon genes (STING) STING1, IRF3, CGAS MAOB 730/4885ADORA3 591/4885AR 3325/4885
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) STING1, IRF3, CGAS MAOB 730/4885ADORA3 591/4885AR 3325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.